Quarterly Results

GLAXOSMITHKLINE PHARMACEUTICALS LTD.

NSE : GLAXOBSE : 500660ISIN CODE : INE159A01016Industry : Pharmaceuticals & DrugsHouse : Glaxosmithkline - MNC
BSE1943.1061.4 (+3.26 %)
PREV CLOSE ( ) 1881.70
OPEN PRICE ( ) 1888.45
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 18731
TODAY'S LOW / HIGH ( )1888.45 1963.15
52 WK LOW / HIGH ( )1228 2649.95
NSE1946.6066.8 (+3.55 %)
PREV CLOSE( ) 1879.80
OPEN PRICE ( ) 1890.45
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 1946.60 (91)
VOLUME 120032
TODAY'S LOW / HIGH( ) 1890.45 1962.35
52 WK LOW / HIGH ( )1227 2524
Quarters
Select year  
( in Million)
Particulars
Dec 2023
Sep 2023
Jun 2023
Mar 2023
Audited / UnAudited
UnAudited
UnAudited
UnAudited
Audited
Net Sales
8052.6
9569.9
7616.6
7874.5
Total Expenditure
5872
6675
6177.8
6177.1
PBIDT (Excl OI)
2180.6
2894.9
1438.8
1697.4
Other Income
281.1
282.1
364.4
276.6
Operating Profit
2461.7
3177
1803.2
1974
Interest
3.2
4.3
2.8
6.5
Exceptional Items
-1633.1
NA
173
104
PBDT
825.40
3172.7
1973.4
2071.5
Depreciation
171.1
181.1
163.6
171.8
Profit Before Tax
654.30
2991.6
1809.8
1899.7
Tax
197.1
816.5
487.3
565.4
Provisions and contingencies
NA
NA
NA
NA
Profit After Tax
457.20
2175.1
1322.5
1334.3
Extraordinary Items
NA
NA
NA
NA
Prior Period Expenses
NA
NA
NA
NA
Other Adjustments
NA
NA
NA
NA
Net Profit
457.20
2175.1
1322.5
1334.3
Minority Interest
NA
NA
NA
NA
Shares of Associates
Other related items
Misc. Expenses Written off
NA
NA
NA
NA
Consolidated Net Profit
457.2
2175.1
1322.5
1334.3
Equity Capital
1694.1
1694.1
1694.1
1694.1
Face Value (IN RS)
10
10
10
10
Reserves
NA
NA
NA
NA
Calculated EPS
2.69
12.83
7.80
7.87
Calculated EPS (Annualised)
10.79
51.35
31.22
31.50
No of Public Share Holdings
42351510
42351510
42351510
42351510
% of Public Share Holdings
25
25
25
25
 
NA
NA
NA
NA
PBIDTM% (Excl OI)
27.07
30.25
18.89
21.55
PBIDTM%
30.57
33.19
23.67
25.06
PBDTM%
10.25
33.15
25.90
26.30
PBTM%
8.12
31.26
23.76
24.12
PATM%
5.67
22.72
17.36
16.94
 
Notes
Notes
Notes
Notes

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.